Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668823 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy in Treating Patients With Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01668823 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 17 participants.
The verdict
NCT01668823, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.
Interventions
- DRUG HPPH
- DRUG photodynamic therapy
- PROCEDURE therapeutic bronchoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01668823
The ClinicalTrials.gov registry entry for NCT01668823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which HPPH is the first listed.
NCT01668823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01668823 about?
NCT01668823 is a clinical study titled "Photodynamic Therapy in Treating Patients With Lung Cancer". This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.
What is the current status of trial NCT01668823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2004-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01668823?
The interventions under investigation include: HPPH (DRUG), photodynamic therapy (DRUG), therapeutic bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT01668823?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.